Brief: Shenzhen Hepalink Pharma Gets Regulatory Approval For Bond Issue
25/03/2022 09:39
March 25 (Reuters) - Shenzhen Hepalink Pharmaceutical Group
Co Ltd 002399.SZ :
* SAYS IT GETS SECURITIES REGULATOR'S APPROVAL FOR BOND
ISSUE
Source text http://www.szse.cn/disclosure/listed/bulletinDetail/index.html?aef96472-20f8-4b70-98de-9a44fedb61e9
Further company coverage: 002399.SZ
(Reporting by Hong Kong newsroom)
((meg.shen@thomsonreuters.com; 852-39525805;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA